Related Experiment Videos
Cellular B-2 microglobulin expression as a prognostic indicator in renal cell carcinoma
I Levin1, O Kuperman, J Goldstein
1Department of Urology, Ben Gurion University of the Negev, Beer-Sheva, Israel.
Acta Oncologica (Stockholm, Sweden)
|January 1, 1991
Summary
Beta-2 microglobulin (B-2M) expression on early-stage renal cell carcinoma tumors indicates a better prognosis. This finding suggests B-2M may predict survival in localized kidney cancer patients.
Area of Science:
- Oncology
- Immunology
- Biomarker Research
Background:
- Renal cell carcinoma (RCC) is a significant health concern.
- Understanding prognostic markers is crucial for patient management.
- Beta-2 microglobulin (B-2M) is a protein found on cell surfaces.
Purpose of the Study:
- To investigate the expression of B-2M on tumor cells in renal cell carcinoma patients.
- To correlate B-2M expression with tumor stage and patient survival.
- To evaluate B-2M as a potential prognostic indicator in early-stage RCC.
Main Methods:
- Studied B-2M expression on tumor cells and normal cell counterparts.
- Analyzed data from 39 patients with renal cell carcinoma.
- Correlated B-2M expression levels with tumor stage and survival data.
Main Results:
- In localized (stage I) RCC, patients with B-2M-expressing tumors had a median survival of 10.2 years versus 3.6 years for those without (p < 0.001).
- For advanced stages (II-IV), B-2M expression showed no significant difference in median survival (3.6 years vs. 2.0 years).
- Tumor cell membrane expression of B-2M was significantly associated with improved survival in early-stage disease.
Conclusions:
- Tumor cell membrane expression of B-2M may serve as a favorable prognostic indicator in early renal cell carcinoma.
- B-2M expression could aid in stratifying risk and guiding treatment decisions for localized RCC.
- Further research is warranted to validate B-2M as a reliable prognostic biomarker in RCC.